Literature DB >> 18451216

Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.

Janos Geli1, Nimrod Kiss, Mohsen Karimi, Jia-Jing Lee, Martin Bäckdahl, Tomas J Ekström, Catharina Larsson.   

Abstract

PURPOSE: This study aims to quantitatively assess promoter and global methylation changes in pheochromocytomas and abdominal paragangliomas and its relation to tumor phenotypes. EXPERIMENTAL
DESIGN: A panel of 53 primary tumors (42 benign, 11 malignant) was analyzed by quantitative bisulfite pyrosequencing. Based on methylation levels in the tumor suppressor genes, p16(INK4A), CDH1, DCR2, RARB, RASSF1A, NORE1A, TP73, APC, DAPK1, p14(ARF), and PTEN, a CpG island methylator phenotype (CIMP) was defined as concerted hypermethylation in three or more genes. Mean Z scores for the hypermethylated promoters were calculated to characterize overall promoter methylation. Global DNA methylation was quantified for LINE-1 promoter sequences and by using luminescent methylation analysis.
RESULTS: Five primary tumors (9.4%) exhibited a CIMP phenotype, four of which were malignant paragangliomas. CIMP was significantly associated with malignant behavior (P = 0.005) and younger age at presentation (P < 0.007) but did not result from BRAF V600E mutation. Global hypomethylation of LINE-1 elements was observed in tumors compared with normal adrenal samples (P < 0.02).
CONCLUSION: We here describe the identification of CIMP in abdominal paragangliomas and a strong association of this phenotype with malignant behavior, as well as young age at presentation. The findings raise a prospective for potential benefits of epigenetically acting drugs for a subgroup of young abdominal paraganglioma patients with adverse prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18451216     DOI: 10.1158/1078-0432.CCR-07-1867

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

2.  Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis.

Authors:  Zhong-Zheng Zhu; Lifang Hou; Valentina Bollati; Letizia Tarantini; Barbara Marinelli; Laura Cantone; Allen S Yang; Pantel Vokonas; Jolanta Lissowska; Silvia Fustinoni; Angela C Pesatori; Matteo Bonzini; Pietro Apostoli; Giovanni Costa; Pier Alberto Bertazzi; Wong-Ho Chow; Joel Schwartz; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2010-09-15       Impact factor: 7.196

3.  Absence of BRAF mutation in pheochromocytoma and paraganglioma.

Authors:  T Vosecka; A Vicha; T Zelinka; P Jencova; K Pacak; J Duskova; J Benes; A Guha; L Stanek; M Kohoutova; Z Musil
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

Review 4.  Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

Authors:  P Mapelli; E O Aboagye; J Stebbing; R Sharma
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

Review 5.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.

Authors:  Lauren Fishbein; Katherine L Nathanson
Journal:  Cancer Genet       Date:  2012 Jan-Feb

6.  Decreased LINE-1 methylation levels in aldosterone-producing adenoma.

Authors:  Chen Chen; Xiaoyu Zhou; Jing Jing; Jing Cheng; Yu Luo; Jiachao Chen; Xi Xu; Fei Leng; Xiaomu Li; Zhiqiang Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

7.  Absence of the BRAF V600E mutation in pheochromocytoma.

Authors:  Johan O Paulsson; F Svahn; J Welander; L Brunaud; P Söderkvist; O Gimm; A Stenman; C C Juhlin
Journal:  J Endocrinol Invest       Date:  2015-12-28       Impact factor: 4.256

Review 8.  Metastatic paraganglioma.

Authors:  Stephanie M J Fliedner; Hendrik Lehnert; Karel Pacak
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

9.  Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.

Authors:  C Christofer Juhlin; Nimrod B Kiss; Andrea Villablanca; Felix Haglund; Jörgen Nordenström; Anders Höög; Catharina Larsson
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

10.  Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors.

Authors:  G Masi; E Lavezzo; M Iacobone; G Favia; G Palù; L Barzon
Journal:  J Endocrinol Invest       Date:  2009-05-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.